United Therapeutics Corp About
United Therapeutics: United Therapeutics is a biotechnology
company focused on developing chronic therapies for life threatening conditions
in three therapeutic areas: cardiovascular, oncology and infectious diseases.
In these segments, United Therapeutics is actively developing five technology
platforms: Prostacyclin Analogs , Immunotherapeutic Monoclonal Antibodies, Glycobiology,
Arginine Formulations, and Telemedicine. REMODULIN
--LEAD PRODUCT--pulmonary
arterial hypertension; Critical limb ischemia (CLI) Remodulin
is the most potent and long lasting of the prostacyclin analogs in use
today, Prostacyclin extends the survival rate of people suffering from primary
pulmonary hypertension, a form of pulmonary arterial hypertension; Prostacyclin
acutely opens blocked blood vessels in the legs of people with critical limb ischemia;
and Longer-acting versions of the prostacyclin molecule, such as Remodulin, improve
the exercise ability and symptoms of people diagnosed with pulmonary arterial
hypertension (PAH). OvaRex-- Ovarian Cancer --
OvaRex is an investigational immunotherapeutic monoclonal antibody ( . UT-231B
--Hepatitis C --UT 231-B, an imonsugar, alters the assembly of viruses
and thereby prevent them from being able to continue infecting and replicating
other cells. More
on
United Therapeutics Key
Statistics for United Therapeutics
Basic
Chart for United Therapeutics